Germany’s CureVac AG is about to launch third phase clinical trials of its coronavirus vaccine candidate, the company’s CEO, Franz-Werner Haas, said on Thursday. The jab could get final approval by September 2021.
The company seeks to launch its third and final vaccine trial phase “as soon as possible,” Haas told journalists during an online media conference. The study is expected to involve 36,000 participants and be completed in about three months.
Continue reading https://on.rt.com/auu2